Research and Markets: Determine the Impact of the ENHANCE Study on Vytorin and Zetia Use

DUBLIN, Ireland--(BUSINESS WIRE)--Jun 23, 2008 - Research and Markets (http://www.researchandmarkets.com/research/4e90d7/vytorin_wave_two) has announced the addition of the "Vytorin: Wave Two - Impact of ENHANCE Trial" report to their offering.

A Survey of One-Hundred Three US-based PCP's and Cardiologists

Deliverable: Survey with key findings.

Study Description:

Topic: Vytorin: Wave Two -- Impact of ENHANCE Trial

Respondent Type: Physicians

Specialties Covered: Primary Care and Cardiology

Region: United States Only

Methodology

- Online survey, self-administered via a Panel Intelligence website

- Duration: 10 minutes

- Size: 72 PCP's and 31 Cardiologists for 103 respondents

- Fielding Dates: April 1st to April 4th, 2008

Inclusion Criteria and Respondent Demographics:

- US-based

- 2 to 30 years of experience post-training

- Minimum of 75% professional time spent in clinical practice

- Writes at least 20 prescriptions for Zetia and Vytorin (combined) in an average month

Companies Mentioned:

- AstraZeneca

- Pfizer

- Merck/Schering-Plough Pharmaceuticals

- Merck & Co

For more information visit http://www.researchandmarkets.com/research/4e90d7/vytorin_wave_two

Contact

Research and Markets
Laura Wood
Senior Manager
Fax from USA: 646-607-1907
Fax from rest of the world: +353-1-481-1716
press@researchandmarkets.com

Posted: June 2008

View comments

Hide
(web4)